Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia

Cell Rep Med. 2023 Jul 18;4(7):101108. doi: 10.1016/j.xcrm.2023.101108. Epub 2023 Jul 10.

Abstract

We systematically investigate functional and molecular measures of stemness in patients with acute myeloid leukemia (AML) using a cohort of 121 individuals. We confirm that the presence of leukemic stem cells (LSCs) detected through in vivo xenograft transplantation is associated with poor survival. However, the measurement of leukemic progenitor cells (LPCs) through in vitro colony-forming assays provides an even stronger predictor of overall and event-free survival. LPCs not only capture patient-specific mutations but also retain serial re-plating ability, demonstrating their biological relevance. Notably, LPC content represents an independent prognostic factor in multivariate analyses including clinical guidelines of risk stratification. Our findings suggest that LPCs provide a robust functional measure of AML, enabling quantitative and rapid assessment of a wide range of patients. This highlights the potential of LPCs as a valuable prognostic factor in AML management.

Keywords: acute myeloid leukemia; cancer stem cell; colony forming unit; leukemic progenitor cell; leukemic stem cell; prognostic; survival; xenotransplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Prognosis